Whether pelvic lymph node dissection during radical prostatectomy offers an oncological benefit remains unknown. This study will compare extended pelvic lymph node dissection versus no dissection in PSMA PET-negative, Grade Group 2 and PSA > 20 ng/ml or Grade Group 3 or higher prostate cancer patients scheduled for surgery. The study will be conducted across all major urological clinics in Switzerland.
